Compare State Street PDR S&P Retail ETF (XRT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street PDR S&P Retail ETF vs Zoetis Inc — how do they compare? State Street PDR S&P Retail ETF trades at $84.12 (market cap $389.66M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 77.5× State Street PDR S&P Retail ETF's market cap, and Zoetis Inc pays a 2.9% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street PDR S&P Retail ETF for 45 Days and Zoetis Inc for 70 Days on average.
| XRT | ZTS | |
|---|---|---|
Market Cap | $389.66M | $30.20B |
Volume | 4,275,820 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $92.35 | $147.53 |
52-Week Low | $77.28 | $69.09 |
Typical Hold Time | 45 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRT trades at $84.09, up 1.42% with a bullish technical signal despite mixed moving averages and oscillators. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with Seeking Alpha noting underperformance against IVV YTD. Recent retail sales data shows volatility, with August rebounding 1.2% after July's unexpected 0.6% decline. The holiday season projection of $1 trillion in sales provides potential upside catalyst.
The retail ETF's outlook remains challenged by macroeconomic pressures, though selective consumer spending and potential Fed easing could support recovery. Key risks include persistent inflation and interest rate sensitivity, while technical support at $81-83 levels provides near-term stability. Analyst sentiment appears cautious given the unsupportive macro environment heading into 2027.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
